Activated Vegfr2/KDR Pathway in Tumour Cells and Tumour Associated Vessels of Colorectal Cancer

Authors: Adrian HL HarrisKevin C GatterMichael I KoukourakisAlexandra N GiatromanolakiEfthimios L SivridisHelen TurleyGregory I ChlouverakisEkaterini Vourvouhaki
Year: 2007
Times cited: 61

Key People For Colorectal Cancer

Top KOLs in the world
Ahmedin * *****
united states breast cancer addis ababa
Rebecca * ******
united states colorectal cancer incidence rates
Freddie *** ****
cancer incidence nordic countries mortality rates
Jacques ******
cancer incidence global burden latin america
Charles ******* *****
colorectal cancer physical activity microsatellite instability
Bert **********
colorectal cancer somatic mutations tumor dna

Activated Vegfr2/kdr Pathway In Tumour Cells And Tumour Associated Vessels Of Colorectal Cancer


BACKGROUND: Vascular endothelial cell growth factor (VEGF) acts by phosphorylating specific tyrosine kinase receptors on endothelial cell membrane promoting angiogenesis. The study of the activation status of VEGF receptors in human malignancies has recently become feasible by means of specific monoclonal antibodies recognising the phosphorylated form of these receptors.

MATERIALS AND METHODS: In the current study, we investigate the expression of the phosphorylated VEGFR2/KDR receptor in normal colon and colorectal adenocarcinomas in parallel with histopathological parameters, prognosis and the expression of the 'hypoxia inducible factor' HIF1alpha.

RESULTS: pVEGFR2/KDR was weakly expressed in the normal colon, but it was expressed strongly in the cytoplasm and nuclei of cancer cells and in the tumour associated vasculature, mainly at the invading tumour edge. pVEGFR2/KDR expression in cancer cells was significantly associated with a tumour diameter > 6 cm (P = 0.04), poor histological differentiation (P = 0.004) and with high CEF1alpha expression (P = 0.05). High pVEGFR2/KDR expressing vascular density was significantly related with a high VEGF and HIF1alpha expression in cancer cells (P = 0.02 and 0.03, respectively). This was also related significantly to high pVEGFR2/KDR expression in cancer cells. In multivariate analysis, the most significant predictors for death were lympho-vascular invasion (P < 0.001) followed by VEGF (P = 0.014), node status (P = 0.015), standard vascular density (P = 0.022) and necrosis (P = 0.032).

CONCLUSIONS: pVEGFR2 receptors are largely expressed in colon cancer cells and intratumoural vasculature. As VEGF targeting agents enter the clinical practice, the role of monoclonal antibodies recognising the phosphorylated form of VEGF receptors as predictors of response to targeted therapies should be sought in clinicopathological trials.

to see all concepts, it's free!